Fetal gene therapy: opportunities and risks.
Advances in human prenatal medicine and molecular genetics have allowed the diagnosis of many genetic diseases early in gestation. In-utero transplantation of allogeneic hematopoietic stem cells (HSC) has been successfully used as a therapy in different animal models and recently also in human fetuses. Unfortunately, clinical success of this novel treatment is limited by the lack of donor cell engraftment in non-immunocompromised hosts and is thus restricted to diseases where the fetus is affected by severe immunodeficiency. Gene therapy using genetically modified autologous HSC circumvents allogeneic HLA barriers and constitutes one of the most promising new approaches to correct genetic deficits in the fetus. Recent developments of strategies to overcome failure of efficient transduction of quiescent hematopoietic cells include the use of new vector constructs and transduction protocols. These improvements open new perspectives for gene therapy in general and for prenatal gene transfer in particular. The fetus may be especially susceptible for successful gene therapy due to the immunologic naiveté of the immature hematopoietic system during gestation, precluding an immune reaction towards the transgene. Ethical issues, in particular those regarding treatment safety, must be taken into account before clinical trials with fetal gene therapy in human pregnancies can be initiated.
Dept. of Obstetrics and Gynecology, and Department of Research, Inselspital, Bern University Hospital and University of Bern, Switzerland.
Anna M
AM
Wagner
Andreina
A
Schoeberlein
Daniel
D
Surbek
D005260:Female; D005315:Fetal Diseases / Q000628:therapy*; D046128:Fetal Therapies / Q000009:adverse effects / Q000941:ethics / Q000379:methods*; D018014:Gene Transfer Techniques; D030342:Genetic Diseases, Inborn / Q000628:therapy*; D015316:Genetic Therapy / Q000009:adverse effects / Q000941:ethics / Q000379:methods*; D005822:Genetic Vectors; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects; D011247:Pregnancy; D012306:Risk